Sanofi

Sanofi FCF/Debt

The Free Cash Flow to Debt Ratio of Sanofi (SAN.PA) as of Nov 7, 2026 is 44.21 %. In the previous year, Free Cash Flow to Debt Ratio was 32.90 % — a change of 34.40% (higher).

FCF/Debt

44.21 %

YoY

34.40%

Last updated:

Free Cash Flow to Debt Ratio of Sanofi is 2025 44.21 % . Free Cash Flow to Debt Ratio of Sanofi was 2024 32.90 % . It decreases by 34.40% higher compared to the previous year.

The Sanofi FCF/Debt history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

FCF/Debt
Date
FCF/Debt
Jan 1, 2018
14.46 EUR
Jan 1, 2019
22.86 EUR
Jan 1, 2020
22.53 EUR
Jan 1, 2021
37.83 EUR
Jan 1, 2022
39.25 EUR
Jan 1, 2023
46.85 EUR
Jan 1, 2024
32.90 EUR
Jan 1, 2025
44.21 EUR
The Sanofi FCF/Debt history
YEARFCF/DebtYoY
44.21 %+34.40%
32.90 %-29.78%
46.85 %+19.37%
39.25 %+3.75%
37.83 %+67.87%
22.53 %-1.43%
22.86 %+58.07%
14.46 %-58.44%
34.80 %+12.04%
31.06 %-16.92%
37.39 %-13.84%
43.39 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Sanofi Stock analysis

What does Sanofi do? Sanofi SA is a French company that was formed in 1973 from a merger of two French pharmaceutical and biotechnology companies. It is one of the largest players in the healthcare industry worldwide and employs over 100,000 employees. The objective of Sanofi is to improve people's lives through innovative medicines and therapies. In this regard, the company pursues a comprehensive business model that focuses on both research and development, as well as the production and distribution of medications and vaccines. The company has different divisions and product lines, which are divided into three business areas: Innovative Medicine, Consumer Healthcare, and Generic Pharmaceuticals. Innovative Medicine utilizes state-of-the-art technologies and scientific knowledge to treat the most challenging diseases. In the area of Consumer Healthcare, the company offers a wide range of over-the-counter products such as vitamins, dietary supplements, cough and cold remedies, as well as oral and dental health products. In the Generic Pharmaceuticals field, the company produces more cost-effective alternatives to expensive brand-name products, providing a variety of generic medications. Sanofi is a leading manufacturer of medications that are of great significance in various areas such as diabetes, oncology, cardiovascular diseases, and neurology. In recent years, the company has also established a strong presence in the field of vaccines. Here, Sanofi develops and produces innovative vaccines against COVID-19, influenza, and other infectious diseases. Sanofi is present in more than 170 countries and collaborates closely with physicians, research institutions, and health authorities to improve healthcare worldwide. The company conducts research and development in various disciplines and invests a significant amount each year in the development of innovative medicines and therapies. Overall, Sanofi SA is an emerging company in the pharmaceutical and healthcare sector. The portfolio of products and therapies offered by Sanofi is extensive and covers many areas of healthcare. Sanofi relies on continuous innovation and continuously works to improve healthcare and enhance the lives of people worldwide. Sanofi is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Sanofi stock

Free Cash Flow to Debt Ratio of Sanofi is 44.21 % in 2025.

Free Cash Flow to Debt Ratio of Sanofi changed from 32.90 % to 44.21 %, representing a 34.40% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow to Debt Ratio Sanofi since 2006 – with annual values, charts, and detailed analysis.

FCF/Debt measures the percentage of total debt that could be repaid from free cash flow. It is a stricter measure than OCF/Debt as it accounts for capital expenditures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Free Cash Flow to Debt Ratio's Sanofi with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — Sanofi

All Key Metrics — Sanofi